GLP-1 agonists like semaglutide produce nausea (usually mild and temporary), constipation, and rare pancreatitis signalsbut side effects typically diminish as your body adjusts over weeks
The MHRA has not approved any transdermal GLP-1 formulations, and all available GLP-1 therapy is administered via subcutaneous injection
In total, 3,918 T2D participants were randomized to receive OW sc semaglutide at doses of 0.5 mg or 1.0 mg, or comparators including placebo, sitagliptin 100 mg, exenatide extended release 2.0 mg, or insulin glargine
Young women with coronary artery disease exhibit higher concentrations of interleukin-6 at baseline and in response to mental stress
Triplet combination of giredestrant, palbociclib, and GPX4 inhibition prevents clonal outgrowth even after short exposure to treatment The combination of CDK4/6 inhibition with endocrine therapies has been transformative for patients with ER+ breast cancer
A.SandersR.ReddyR